DuPont Coumadin
Executive Summary
Company uses $44 mil. litigation reserve to settle multiple state and federal class action lawsuits on its promotion of Coumadin (warfarin). DuPont will pay $44.5 mil. to U.S. consumers and third parties claiming the company discouraged generic substitution for the anticoagulant